Kite Pharma
Santa Monica
California
United States
260 articles with Kite Pharma
-
The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.
-
Appia is developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients.
-
The U.S. FDA approved Gilead and Kite’s Yescarta (axicabtagene ciloleucel) for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
-
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.
-
BioSpace Movers & Shakers, Feb. 12
2/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
2/10/2021
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta ® in Patients With Relapsed or Refractory Large B-cell lymphoma
-
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
2/8/2021
Industry Leader in Cell Therapy and Oncology Drug Development Positioned for Continued Advancement of Kite’s Clinical Programs
-
Kite Pharma has tapped immunotherapy expert Francesco Marincola, a former National Institutes of Health investigator, to helm the company’s cell therapy research.
-
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
1/6/2021
Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. This pres
-
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
12/16/2020
Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe
-
ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope
12/7/2020
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day. -
European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
10/16/2020
-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis -- -- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe -- SANTA MONICA, Calif.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Auth
-
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
9/3/2020
Research Collaboration will Leverage HiFiBiO’s Proprietary Single-Cell Platform to Identify Novel Targets to Support Kite’s Development of Cell Therapies in AML -- SANTA MONICA, Calif. & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML). Through this collaboratio
-
Maryland has become a key part of the strategy for Kite, a Gilead company, and its mission to find a cure for cancer.
-
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
-
The U.S. Food and Drug Administration (FDA) approved Kite Pharma’s Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). Kite is a Gilead Science company.
-
Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe
6/12/2020
Amsterdam Facility will Bring Kite’s Potentially Life-Saving Individualized Treatment Closer to People with Advanced Blood Cancers in the European Region --
-
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
5/29/2020
Yescarta ® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma -- 93 Percent of Patients with Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma Responded to a Single Infusion of Yescarta, with 80 Percent Achieving a Complete Response -- -- Data Presented in an Oral Session During the 2020 American Society of Clinical Oncology Annual Meeting --
-
Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting
5/13/2020
Nine Abstracts, Including Three Oral Presentations, Highlight Leadership in Hematologic Malignancies and Early Progress in Solid Tumors
-
The goal is to support the discovery and development of next-generation drug and engineered cell therapies, specifically with a focus on natural killer (NK) cells.